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CXC Chemokines and Epidermotropic T Cells
The epidermotropism that can be observed in cutaneous T cell
lymphoma (CTCL) is well known but has not been convincingly
explained. Therefore, Tensen et al (p. 222) investigated the expression
of selected chemokines in the affected epidermis of patients with
epidermotropic CTCL. Chemokines are a large family of cytokines
that are involved in the regulation of various leukocyte functions,
including directed migration (chemotaxis). Tensen et al show that the
CXC chemokines lacking the ELR-motif, i.e., interferon gamma-
inducible protein-10 (IP-10) and monokine induced by interferon
gamma (Mig), are expressed in the epidermis of epidermotropic CTCL
but not in non-epidermotropic CTCL or normal human skin. IP-10
and Mig expression parallel the infiltration of neoplastic epidermotropic
T lymphocytes of the CD3/CD4 phenotype. In contrast, infiltration
of the epidermis by CD81 neoplastic T cells, a rare event, is not found
to be accompanied by IP-10 or Mig expression. The authors provide
More on the Actions of Stem Cell Factor (SCF) in Human Skin
SCF interacting with its membrane-bound ligand KIT is critical for
the development and survival of melanocytes. Grichnik et al (p. 233)
investigated the role of SCF in activation of the pigment cells in a
human xenograft model by injecting recombinant human (rh) SCF
intradermally. In a second set of experiments, they injected a murine
anti-human KIT antibody. According to their findings, SCF does not
only increase number, size, and dendricity of melanocytes but also
markedly increases the expression of melanocyte differentiation antigens
such as tyrosinase-related protein 1 (TRP-1) and gp100/pmel17. The
authors show that treatment with the anti-KIT antibody has the
opposite effect with an apparently irreversible loss of melanocytes.
Based on their findings, Grichnik et al suggest that the SCF/KIT
pathway may thus be a target for pharmacologic modulation of disorders
of the pigment cells system. Hiragun et al (p. 213) have investigated
the involvement of platelet-derived growth factor (PDGF) in mast cell
hyperplasia associated with dermal fibrosis. Although there is no
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evidence that IL-8 is not involved in the epidermal accumulation of
CTCL cells based on the lack of mRNA for interleukin-8 (IL-
8), another CXC chemokine with the ELR-motif. This finding is
concordant with the lack of immunoreactivity for the CXCR2 in
suprabasal keratinocytes. The immunoreactivity for CXCR1 of den-
dritic epidermal and dermal cells, however, appears to be unchanged.
Tensen et al state that they do not observe any CXCR1 or CXCR2
reactivity by intraepidermal T lymphocytes.
Although not formally proven, it is possible that IP-10 and Mig are
produced by keratinocytes. Moreover, IP-10 and, to a lesser extent,
Mig, but not IL-8, are correlated with the epidermal infiltration of
neoplastic CD41 T cells in CTCL. The question remains to be
answered, however, of whether IP-10 and Mig expression is responsible
for the migration of the neoplastic T lymphocytes into the epidermis,
or rather represents an epiphenomenon indicating the presence of an
epidermotropic neoplastic T cell subpopulation.
evidence for a direct effect of PDGF on mast cell proliferation, these
investigators have found, in a mast cell/fibroblast coculture system,
that PDGF enhance growth of mouse mast cells via induction of
membrane-bound SCF on fibroblasts. Fibroblasts are needed for mast
cell growth because mast cells display only the β-subunit of the PDGF
receptor (PDGF-R), whereas fibroblasts express mRNA for both a
and β subunits of the PDGF-R. Therefore, bone marrow-derived mast
cells (BMMC) alone do not respond to PDGF by increased DNA
synthesis. The authors confirm their data with a series of experiments
using an anti-SCF antibody to block rhPDGF-induced mast cell growth
and using mast cells from W/Wv mice with a functionally defective
c-kit (SCF-R). Furthermore, the authors show that there is no mast
cell growth when normal BMMC are cocultured with fibroblasts from
Sl/Sld mice that lack a functional membrane-bound SCF. Hiragun et al
thus provide evidence of an IL-3, IL-4-independent pathway for mast
cell proliferation that may be mainly operative in dermal fibrosis
associated with wound healing and scarring.
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MGM — Molecular Genetics of Melanoma
The extension locus encoding the melanocyte stimulating hormone
receptor (melanocortin 1 receptor 5 MC1R) regulates the relative
proportion of protective eumelanin and ‘‘damaging’’ pheomelanin in
mammals. Thus, MC1R is critically involved in pigmentation and sun
sensitivity, which have been reported to be associated with susceptibility
to melanoma.
In a case control study, Ichii-Jones et al (p. 218) have determined
the frequency of three MC1R allelic variants (val92met, asp294his,
asp84glu) in association with skin type and hair color in 190 Caucasian
controls and 306 melanoma cases. Using the Armitage trend test, the
authors identified an association between skin type and MC1R variants
in the group comprising all controls with any one or more of the
alleles tested; however, there were no genotypic associations between
MC1R alleles and hair color, and more importantly, the polymorphisms
at MC1R did not indicate susceptibility candidates for melanoma.
In a second study published in this issue, MacKie et al (p. 269) used
SSCP and subsequent direct sequencing to determine four different
functionally damaging germline mutations of the CDKN2A gene
(p16 5 MTS 1 gene), encoded on chromosome 9p21, in six of 16
families with melanoma. The authors compared those data with the
mutations found in two of 18 individual patients with sporadic multiple
primary melanomas who did not have a family history of melanoma.
They detected CDKN2A mutations in families with only few affected
members. This is the first time that genetics of patients with multiple
primary melanomas but no family history have been studied in detail.
In addition, MacKie et al report a tyr44 stop codon in exon 1 of
CDKN2A in melanoma. The significance of this finding, however, is
not clear. Although p16 mutations are rare in sporadic melanoma, and
not all melanoma families have a CDKN2A mutation, these studies
clearly indicate that it is nevertheless important to follow different
approaches of molecular genetic investigations (case control studies,
disease association studies, and genetic linkage analyses) in a genetically
complex disease such as melanoma.
